Download MendeleyStepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.
Kwiatkowski, J., Liu, B., Pang, S., Ahmad, N.H.B., Wang, G., Poulsen, A., Yang, H., Poh, Y.R., Tee, D.H.Y., Ong, E., Retna, P., Dinie, N., Kwek, P., Wee, J.L.K., Manoharan, V., Low, C.B., Seah, P.G., Pendharkar, V., Sangthongpitag, K., Joy, J., Baburajendran, N., Jansson, A.E., Nacro, K., Hill, J., Keller, T.H., Hung, A.W.(2020) J Med Chem 63: 621-637
- PubMed: 31910010
- DOI: https://doi.org/10.1021/acs.jmedchem.9b01582
- Primary Citation of Related Structures:
6JLR - PubMed Abstract:
Dysregulation of translation initiation factor 4E (eIF4E) activity occurs in various cancers. Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) play a fundamental role in activation of eIF4E. Structure-activity relationship-driven expansion of a fragment hit led to discovery of dual MNK1 and MNK2 inhibitors based on a novel pyridine-benzamide scaffold. The compounds possess promising in vitro and in vivo pharmacokinetic profiles and show potent on target inhibition of eIF4E phosphorylation in cells.
Organizational Affiliation:
Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR) , 10 Biopolis Way, Chromos #05-01/06 , 138670 Singapore.
